A dual inhibitor of both EGFR and ErbB2 tyrosine kinases activity, lapatinib, had been applied mainly in metastatic breast cancer, since in other types of cancer it did not act as an effective inhibitor of the phosphorylation [65, 66]. Here, ERBB2 is linked to cancer.